CA2641871A1 - Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable - Google Patents

Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable Download PDF

Info

Publication number
CA2641871A1
CA2641871A1 CA2641871A CA2641871A CA2641871A1 CA 2641871 A1 CA2641871 A1 CA 2641871A1 CA 2641871 A CA2641871 A CA 2641871A CA 2641871 A CA2641871 A CA 2641871A CA 2641871 A1 CA2641871 A1 CA 2641871A1
Authority
CA
Canada
Prior art keywords
liver injury
pharmaceutical composition
pharmaceutically acceptable
induced liver
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2641871A
Other languages
English (en)
Inventor
Hye Kyung Chang
Yeong Soo Oh
Hyun Ik Shin
Mi Jeong Park
Jung Gyu Park
Yong Han Paik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LG Chem Ltd
Original Assignee
LG Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LG Life Sciences Ltd filed Critical LG Life Sciences Ltd
Priority to CA2641871A priority Critical patent/CA2641871A1/fr
Publication of CA2641871A1 publication Critical patent/CA2641871A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2641871A 2008-10-24 2008-10-24 Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable Abandoned CA2641871A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2641871A CA2641871A1 (fr) 2008-10-24 2008-10-24 Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2641871A CA2641871A1 (fr) 2008-10-24 2008-10-24 Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable

Publications (1)

Publication Number Publication Date
CA2641871A1 true CA2641871A1 (fr) 2010-04-24

Family

ID=42122682

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2641871A Abandoned CA2641871A1 (fr) 2008-10-24 2008-10-24 Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable

Country Status (1)

Country Link
CA (1) CA2641871A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710666A (zh) * 2019-04-19 2021-11-26 株式会社Lg化学 半胱天冬酶抑制剂的前药

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113710666A (zh) * 2019-04-19 2021-11-26 株式会社Lg化学 半胱天冬酶抑制剂的前药

Similar Documents

Publication Publication Date Title
CN1051998C (zh) 异喹啉类化合物、其制备方法及其药物组合物
KR20200029509A (ko) Fxr 작용제
US9040555B2 (en) Antifibrotic compounds and uses thereof
EA028026B1 (ru) Противовирусное соединение, содержащая его фармацевтическая композиция и способ лечения
KR20120139706A (ko) 병형간염 병독억제제로 사용되는 다환잡환화합물
EP1935892A1 (fr) Dérivés d'acide glycyrrhétinique-30-amide et applications
EA028550B1 (ru) Ингибитор грелин-o-ацилтрансферазы
US20100120843A1 (en) Pharmaceutical composition for treating alcohol-induced liver injury comprising (4s,5s)-5-fluoromethyl-5-hydroxy-4-(amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof
CN106883279B (zh) 一种前药、其制备方法、药物组合物及其用途
CN114667289A (zh) 杂芳基血浆激肽释放酶抑制剂
CN111393399A (zh) 麦考酚酸的前体药物及其制备方法
JP5128126B2 (ja) 置換ジケトピペラジンオキシトシンアンタゴニストとしてのその使用
US20220401423A1 (en) Methods for treating inflammatory bowel disease
CN111471080B (zh) ocotillol型人参皂苷元A环并氨基噻唑环衍生物及制备方法
US20230374030A1 (en) Solid-state forms of relugolix
CN111202737B (zh) 雷公藤红素酰胺衍生物在制备治疗自身性免疫疾病药物的应用
KR20200011974A (ko) 요산 배출을 촉진시키는 urat1 억제제
CN114262319A (zh) 一类双功能分子、其制备方法及其应用
CA2641871A1 (fr) Composition pharmaceutique pour le traitement de l'atteinte hepatique d'origine alcoolique (4s, 5s)-5-fluoromethyl-5-hydroxy-4-({¬(5r)-5-isopropyl-3-(isoquinolin-1-yl)- 4,5-dihydro-5-isoxazolyl|carbonyl}amino)-dihydrofuran-2-one ou son sel pharmaceutiquement acceptable
CN102030709B (zh) 用作加压素受体拮抗剂的苯并氮杂卓类化合物
WO2023056936A1 (fr) Dérivé nucléotidique, composition pharmaceutique associée et son utilisation
WO2004026298A1 (fr) Derives de triptolide presentant un puissant effet immunosuppresseur et une forte solubilite dans l'eau, utilisations de ces derives de triptolide
CN115192573A (zh) 盐酸去亚甲基小檗碱在制备治疗肺纤维化药物中的应用
KR20220155356A (ko) 파르네소이드 x 수용체 효능제의 결정형
AU2008243206A1 (en) Pharmaceutical composition for treating alcohol-induced liver damage comprising (4S,5S)-5-fluoromethyl-5-hydroxy-4-({[(5R)-5-isopropyl-3-(isoquinolin-1-yl)-4,5-dihydro-5-isoxazolyl]carbonyl}amino)-dihydrofuran-2-one or pharmaceutically acceptable salt thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead